BrainStorm

Company Overview

Snapshot

Founded in January 2000, BrainStorm operates with 11–50 employees. The company has raised a total of $67.13M across 17 funding rounds from 3 investors. In October 2003, BrainStorm became public on NASDAQ.

Business overview

BrainStorm Cell Therapeutics is a biotechnology company focused on developing autologous stem cell therapeutics for neurodegenerative disorders, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). Its core technology, NurOwn®, transforms mesenchymal stem cells into neurotrophic factor-secreting cells to deliver growth factors to affected areas. The company serves the healthcare and life sciences industries, operating within the pharmaceuticals and medical biotechnology sectors.

Strategic signal

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize the development of NurOwn® for ALS treatment. This decision followed an FDA advisory committee meeting that reviewed NurOwn®, indicating a critical pivot in the company's clinical and regulatory strategy. This signals to investors a focused effort on advancing its lead candidate despite regulatory challenges, aiming to streamline operations and resource allocation for key clinical trials and submissions.

Company Intelligence Q&A

What is BrainStorm's primary therapeutic focus?

BrainStorm Cell Therapeutics primarily focuses on developing autologous stem cell therapeutics for neurodegenerative disorders, specifically Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS).

When did BrainStorm become a public company?

BrainStorm became public on NASDAQ in October 2003.

What was the outcome of the FDA advisory committee meeting regarding NurOwn®?

In September 2023, FDA advisers voted against the experimental ALS treatment NurOwn®, leading to a stock trading halt and subsequent strategic realignment by BrainStorm Cell Therapeutics.

What strategic decision did BrainStorm make in October 2023?

In October 2023, BrainStorm Cell Therapeutics announced a strategic realignment to prioritize the development of NurOwn® for the treatment of ALS.

Has BrainStorm received any grants for its research?

In November 2019, BrainStorm Cell Therapeutics received a research grant award from the National Multiple Sclerosis Society. In April 2020, the company was awarded a grant from the Israel Innovation Authority.